Applications
4basebio develops synthetic DNA for vaccines, gene editing, cell therapy, and targeted delivery to support research and development.

4basebio makes cell-free synthetic DNA for therapeutics and vaccines for pharma and biotech innovators, avoiding plasmid DNA bottlenecks.
4basebio.comCrawled Nov 6, 2026
4basebio develops synthetic DNA for vaccines, gene editing, cell therapy, and targeted delivery to support research and development.
Brochures and flyers detail 4basebio’s synthetic DNA products and services.
4basebio provides synthetic DNA evaluation products for AAV, mRNA, gene editing, and reporter genes to integrate into existing workflows.
4basebio offers custom DNA manufacturing services to remove bottlenecks and produce high-quality GMP DNA for genetic therapies.
4basebio’s synthetic DNA technology simplifies therapeutics development by providing high-quality DNA without plasmid production challenges.
On-demand videos and webinars feature expert insights from 4basebio and industry partners on synthetic DNA, mRNA, and advanced therapies.
The page shares articles and media on 4basebio’s synthetic DNA design, manufacturing, and applications for therapies, vaccines, and gene editing.
4basebio specializes in synthetic DNA design and manufacturing for vaccines, gene editing, and therapeutics.
Case studies demonstrate how 4basebio’s synthetic DNA supports cell and gene therapy, mRNA, and vaccine development with faster manufacturing and scalable GMP solutions.
The page provides updates on 4basebio’s synthetic DNA design, manufacturing, and applications in gene therapy, vaccines, and research.
4basebio produces synthetic DNA for mRNA vaccines, gene editing, and therapeutics.
4basebio collaborates with Genezen to combine synthetic DNA technology with viral vector development for gene therapy manufacturing.
4basebio will supply clinical-grade opDNA for a multinational pharmaceutical innovator’s Phase I cell therapy trial, with TriLink BioTechnologies as the contractor.
15 JUN 2026 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, today announces the appointment of Dr. Jeff Coller as member of the Strategic Advisory Board, effective immediately.
4basebio’s enzymatic ssDNA Platform won ‘Synthetic Biology Innovation of the Year’ in the BioTech Breakthrough Awards.
4basebio’s expertise includes synthetic DNA manufacturing, gene editing, and vaccine development.
The page lists 4basebio’s regulatory news, including official updates and investor disclosures.
4basebio manufactures advanced synthetic DNA for therapeutics, vaccines, gene editing, and research, delivering high-purity, customizable DNA.
The 4basebio Board of Directors includes executive and independent non-executive members overseeing strategy, governance, audit, and remuneration.
View the key advisers to 4basebio plc, including its nominated adviser, brokers, auditors and legal advisers supporting the company’s AIM listing.
4basebio manufactures synthetic, cell-free DNA for gene therapy, mRNA, and vaccine innovators, offering high-purity and scalable solutions.
4basebio’s corporate governance framework covers board structure, risk oversight, and compliance with the QCA Corporate Governance Code.
Authorized distribution partners worldwide provide access to 4basebio’s synthetic DNA solutions across the Americas, Europe, and Asia Pacific.
The page outlines 4basebio’s investment case, including its synthetic DNA technology, GMP manufacturing, and opportunities in cell and gene therapy and mRNA markets.
The page provides contact information for inquiries about 4basebio’s synthetic DNA solutions and collaborations.
Find answers to common questions about 4basebio's synthetic DNA technologies and manufacturing capabilities.
4basebio specializes in synthetic DNA design and manufacturing for vaccines, gene therapy, and genetic research, offering fast, safe, and scalable solutions.
4basebio specializes in synthetic DNA design and manufacturing for vaccines, gene therapy, and genetic research, offering fast, safe, and scalable solutions.
The Privacy and Cookie Policy explains how 4basebio collects, uses, and protects personal data and website visitor information.
The website disclaimer covers terms of use, liability, intellectual property, and investor information.
The Modern Slavery Statement outlines 4basebio’s commitment to preventing slavery and human trafficking in operations and supply chains.
4basebio wins the **‘Synthetic Biology Innovation of the Year’** award in the 6th annual BioTech Breakthrough Awards for its **enzymatic single-stranded DNA (ssDNA) platform**, designed for developing genomic medicines. The company specializes in producing DNA enzymatically, differentiating itself in the synthetic biology space. The accolade is granted by **BioTech Breakthrough**, an independent market intelligence firm recognizing leading biotech innovations.
4basebio and TriLink BioTechnologies collaborate to advance a **leading pharmaceutical company’s Phase I cell therapy program**. The partnership builds on their existing relationship with the unnamed Tier 1 pharmaceutical customer, expanding into cell therapy applications.
4basebio and Genezen collaborate to integrate synthetic, cell-free DNA technology with viral vector manufacturing expertise. The partnership aims to accelerate gene therapy programs from early development through clinical and commercial production stages. Both companies combine their platforms to enhance viral vector manufacturing efficiency and scalability.
4basebio PLC adds Dr. Jeff Coller, a globally recognized expert in mRNA biology, to its Strategic Advisory Board. His appointment supports the company’s focus on scalable manufacturing for next-generation nucleic acid therapeutics. Dr. Coller’s experience in mRNA translation aligns with 4basebio’s mission in synthetic DNA production for advanced therapies.
4basebio PLC introduces a high-capacity single-stranded DNA (ssDNA) platform designed for next-generation gene editing. The enzymatic ssDNA products enable targeted genetic therapies, advanced cell engineering, and nucleic acid-based medicines. The company aims to support safer and more precise therapeutic development through its synthetic DNA manufacturing capabilities.
4basebio leases a new **innovation hub and manufacturing facility in Cambridge, UK** to scale synthetic DNA production for gene therapies, mRNA vaccines, genome editing, and DNA vaccines. The expansion supports rising demand for high-quality nucleic acids in next-generation therapeutics. The company specializes in synthetic DNA manufacturing for advanced biomedical applications.